Showing 2,101 - 2,120 results of 17,627 for search '"The Progressive"', query time: 0.10s Refine Results
  1. 2101
  2. 2102
  3. 2103
  4. 2104
  5. 2105
  6. 2106
  7. 2107
  8. 2108
  9. 2109
  10. 2110
  11. 2111
  12. 2112
  13. 2113
  14. 2114

    Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial by Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Changping Shan, Xinlan Liu, Yumin Yao, Bing Zhao, Shusen Wang, Xiaohua Zeng, Changlu Hu, Xi Yan, Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, Xinhong Wu, Deyong Zhang, Tong Li

    Published 2025-01-01
    “…Progression-free survival (PFS) assessed by investigators was significantly improved in lerociclib arm versus placebo arm (11.07 vs 5.49 months; hazard ratio, 0.451, 95% CI: 0.311-0.656, P = 0.000016), meeting the pre-specified primary endpoint. …”
    Get full text
    Article
  15. 2115
  16. 2116
  17. 2117
  18. 2118
  19. 2119
  20. 2120